Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-27Clinical Trial Results: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) [Phase 1, Phase 2]
Phase 1/2 trial evaluating pembrolizumab with or without investigational agents as neoadjuvant therapy in stage III melanoma; results comple…
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Results: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating a triple immune checkpoint blockade (INCMGA00012 anti-PD-1, INCAGN02385 anti-LAG-3, INCAGN02390 anti-TIM-3) in ad…
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) [Phase 1, Phase 2]
Phase 1/2 substudy evaluating pembrolizumab in combination with investigational agents for PD-1 refractory melanoma; results completed and p…
-
CLINICAL_TRIALS trial_result · 2026-08-06Clinical Trial Results: High Dose IL-2 in Combination With Anti-PD-1 [Phase 2]
Phase 2 trial evaluating high-dose interleukin-2 in combination with anti-PD-1 in melanoma and renal cell carcinoma (metastatic); study term…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating HBI-8000 in combination with nivolumab for melanoma, renal cell carcinoma, and non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
EMA approval · 2026-07-22EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
The EMA authorises Braftovi (encorafenib) for melanoma and colorectal neoplasms.
-
EMA approval · 2026-07-21EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG
Opdualag, a nivolumab and relatlimab combination, has been authorised for melanoma in the EU.
-
CLINICAL_TRIALS trial_result · 2026-07-09Clinical Trial Results: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study of pegylated IL-10 (pegilodecakin) in adults with advanced solid tumors; results from a first-in-human trial assessing safety …
-
CLINICAL_TRIALS trial_result · 2026-07-02Clinical Trial Results: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab [Phase 2]
Phase 2 study evaluating TLR9 agonist vidutolimod (CMP-001) in combination with nivolumab versus nivolumab alone in melanoma; results comple…
-
EMA approval · 2026-07-01EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
EMA authorises Braftovi (Encorafenib) for melanoma and colorectal neoplasms.
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-06-24EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…
-
CLINICAL_TRIALS trial_result · 2026-06-18Clinical Trial Results: Family Lifestyles, Actions, and Risk Education Intervention: Version 2 [NA]
A completed clinical trial evaluating a family lifestyle and risk education intervention related to melanoma in children.
-
CLINICAL_TRIALS trial_result · 2026-06-16Clinical Trial Results: Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating nivolumab as treatment for Stage IIB-IIC melanoma that can be surgically removed; results completed with results po…
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Results: Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating pembrolizumab plus lenvatinib for brain metastases from melanoma or renal cell carcinoma; study terminated with res…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma [Phase 3]
Phase 3 trial update on subcutaneous nivolumab plus relatlimab fixed-dose combination for previously untreated metastatic or unresectable me…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating IT-hu14.18-IL2 with radiation, nivolumab and ipilimumab in melanoma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II [Phase 3]
A Phase III randomized non-inferiority trial evaluating superparamagnetic iron oxide for sentinel lymph node localization in cutaneous melan…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib in combination with pembrolizumab for unresectable or metastatic melanoma that is refractory to PD-1 inh…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating immunotherapy or targeted therapy with or without stereotactic radiosurgery for brain metastases from melanoma or…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: ctDNA for Early Detection of Recurrence in Melanoma
An update on a trial evaluating ctDNA for the early detection of melanoma recurrence. The study is currently not recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab [Phase 2]
Phase 2 clinical trial evaluating adoptive cell therapy with tumor infiltrating lymphocytes plus interleukin-2 for metastatic melanoma, give…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study [EARLY_Phase 1]
An early-phase immune checkpoint inhibitor drug–drug interaction study is described with not-yet-recruiting status, covering gastrointestina…